CA2124672A1 - Cytokines a residu cysteine non apparie et leurs conjugues - Google Patents

Cytokines a residu cysteine non apparie et leurs conjugues

Info

Publication number
CA2124672A1
CA2124672A1 CA002124672A CA2124672A CA2124672A1 CA 2124672 A1 CA2124672 A1 CA 2124672A1 CA 002124672 A CA002124672 A CA 002124672A CA 2124672 A CA2124672 A CA 2124672A CA 2124672 A1 CA2124672 A1 CA 2124672A1
Authority
CA
Canada
Prior art keywords
cytokine
cysteine residue
conjugated
site
unpaired cysteine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002124672A
Other languages
English (en)
Inventor
Tse W. Chang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanox Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2124672A1 publication Critical patent/CA2124672A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A61K47/557—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells the modifying agent being biotin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA002124672A 1991-12-10 1992-12-10 Cytokines a residu cysteine non apparie et leurs conjugues Abandoned CA2124672A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80545291A 1991-12-10 1991-12-10
US805,452 1991-12-10

Publications (1)

Publication Number Publication Date
CA2124672A1 true CA2124672A1 (fr) 1993-06-24

Family

ID=25191607

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002124672A Abandoned CA2124672A1 (fr) 1991-12-10 1992-12-10 Cytokines a residu cysteine non apparie et leurs conjugues

Country Status (5)

Country Link
EP (1) EP0618927A4 (fr)
JP (1) JP2704214B2 (fr)
AU (1) AU666914B2 (fr)
CA (1) CA2124672A1 (fr)
WO (1) WO1993012142A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6165458A (en) * 1997-12-26 2000-12-26 Pharmaderm Laboratories Ltd. Composition and method for dermal and transdermal administration of a cytokine
WO2000071713A1 (fr) 1999-05-20 2000-11-30 Scios Inc. Variants du facteur de croissance endotheliale
CA2374050A1 (fr) * 1999-05-20 2000-11-30 Scios Inc. Dimeres, facteurs de croissance de l'endothelium vasculaire
DE10144252A1 (de) * 2001-08-31 2003-03-27 Fraunhofer Ges Forschung Nanopartikel mit daran immobilisiertem biologisch aktivem TNF
GB0123262D0 (en) * 2001-09-27 2001-11-21 Adprotech Ltd Polymeric compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2533209B1 (fr) * 1982-09-22 1985-11-08 Centre Nat Rech Scient Lipopeptides, leur obtention et leur application comme emulsifiants
JP2514950B2 (ja) * 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
US5082967A (en) * 1988-06-16 1992-01-21 Washington University Novel fatty acid analog enzyme substrates
IL87055A (en) * 1988-07-08 1994-06-24 Illana Gozes Conjugates of vasoactive intestinal peptide (vip) and of fragments thereof and pharmaceutical compositions comprising them
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
WO1991012229A1 (fr) * 1990-02-12 1991-08-22 National Research Council Of Canada Procede de preparation de derives acyles de composes acylables
ES2113354T3 (es) * 1990-05-04 1998-05-01 American Cyanamid Co Estabilizacion de somatotropinas y otras proteinas por modificacion de residuos de cisteina.

Also Published As

Publication number Publication date
JP2704214B2 (ja) 1998-01-26
WO1993012142A1 (fr) 1993-06-24
JPH07502508A (ja) 1995-03-16
AU3323593A (en) 1993-07-19
EP0618927A1 (fr) 1994-10-12
AU666914B2 (en) 1996-02-29
EP0618927A4 (fr) 1995-05-24

Similar Documents

Publication Publication Date Title
TWI406672B (zh) 生物效力增進的β干擾素聚合物共軛體
DE69735202T2 (de) Stimulierung wirtseigener abwehrmechanismen gegen krebs
ES2267188T3 (es) Metodos para el tratamiento de pacientes que padecen esclerosis multiple usando interferon consenso.
JP2018058884A (ja) 組換えエリスロポエチンと部分的に組合されたｉｌ−１インヒビターおよびｔｎｆアンタゴニストの貧血治療用途
JPH04506006A (ja) ヒトサイトカイン、インターロイキン―９
US5543140A (en) Method and use of IL-1α
JPH07505894A (ja) インターフェロンで病気を治療するための副作用の少ない方法および組成物
JP2000507917A (ja) 持続的低用量サイトカイン注入治療
JP2008509889A (ja) ペグ化インターフェロンα−１ｂ
SK515087A3 (en) Methot for producing hematopoietin il-6
JPH10513440A (ja) 化学的に修飾したインターフェロン
US5250296A (en) Immunostimulant agent containing interleukin-2 and 5'-deoxy-5-fluorouridine
CA2124672A1 (fr) Cytokines a residu cysteine non apparie et leurs conjugues
Peeva et al. Rheumatoid arthritis exacerbation caused by exogenous interleukin‐12
WO1992019259A1 (fr) Molecules ciblees sur un recepteur de l'interleukine destinees a traiter l'arthrite inflammatoire
EP0422010A1 (fr) Traitement du melanome par une therapie combinant l'il-2 et le dtic
US5997858A (en) Stimulation of host defense mechanisms against tumors
JPH08508035A (ja) 可溶性レセプターと複合化したリガンドを含む医薬組成物
DE69735204T2 (de) Stimulierung von wirtseigenen abwehrmechanismen gegen tumore
US6627200B1 (en) Utilization of CD 137 in order to promote the proliferation of peripheral monocytes
CA1291706C (fr) THERAPIE A BASE D'INTERFERON-.beta. ET D'INTERLEUKINE-2
KR20160134989A (ko) 인간 인터류킨-2 단백질을 포함하는 약학조성물
CA2200879A1 (fr) Remede contre les maladies osseuses
JPH05117163A (ja) 前胸腺細胞の成熟のための医薬製剤
CN116987666A (zh) 靶向sting通路制备治疗性nk细胞

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead